Catalent Pharma Solutions has acquired a license to market Redwood Bioscience 's proprietary SMARTag precision protein-chemical engineering technology.
Catalent Pharma Solutions announced in a statement that it has acquired an exclusive license to market Redwood Bioscience’s proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs).
Redwood’s novel, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety, and stability. Catalent offers a proprietary GPEx cell line expression system, a biomanufacturing Center of Excellence in Madison, Wis., and range of bioanalytical and fill-finish services.
ADCs combine the targeted binding specificity and half-life benefits of monoclonal antibodies with the potency advantages of small molecule chemotherapy or therapeutic agents. With the FDA’s recent approval of Genentech’s T-DM1 (Kadcycla™) for metastatic breast cancer, and a large and growing list of products in clinical and pre-clinical development, ADCs are emerging as one of the fastest growing development areas in biologic anti-cancer treatment, according to the statement.
Under the terms of the agreement, Catalent will have the exclusive right to sub-license the SMARTag technology to customers and will work with Redwood to co-market the technology and support sub-license programs. Catalent will also take a minority equity stake in Redwood, which may increase over time up to a potential acquisition.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypotheses is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The author highlights the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.